Enabling Faster Drug Discovery in the Cloud
Cryo-EM has emerged as a powerful tool for enabling rapid advances in drug discovery. The scale, simplicity, and economics of AWS promises to transform cryo-EM workflows even further.
However, processing and analyzing large cryo-EM datasets in AWS requires the right architecture and the right data platform.
Join this chat with Baris Guler, HPC Practice Manager at Clovertex to learn:
- How cryo-EM is impacting drug discovery and the main challenges that exist
- Why traditional storage approaches aren’t meeting the demands of cryo-EM applications like CryoSPARC
- How they leverage WEKA with AWS to enable faster drug discovery workflows
- What benchmarks they have seen and recommendations you can use
Cryo-EM has emerged as a powerful tool for enabling rapid advances in drug discovery. The scale, simplicity, and economics of AWS promises to transform cryo-EM workflows even further.
However, processing and analyzing large cryo-EM datasets in AWS requires the right architecture and the right data platform.
Join this chat with Baris Guler, HPC Practice Manager at Clovertex to learn:
- How cryo-EM is impacting drug discovery and the main challenges that exist
- Why traditional storage approaches aren’t meeting the demands of cryo-EM applications like CryoSPARC
- How they leverage WEKA with AWS to enable faster drug discovery workflows
- What benchmarks they have seen and recommendations you can use
Speakers
-
Baris Guler
HPC Practice Manager
Clovertex -
Phil Curran
Cloud Strategist
WEKA